Acutis will develop the new genomic assay, based on its approved lab-developed tests, by combining SOPHiA DDM for Hereditary Cancers Solution with its laboratory analysis technologies
Acutis selects SOPHiA to create new NGS test. (Credit: National Cancer Institute on Unsplash)
Acutis Diagnostics has selected SOPHiA GENETICS, a cloud-native healthcare software company, to use the latter’s platform for developing a new next-generation sequencing (NGS) test.
The cloud-native platform, dubbed SOPHiA DDM, is designed to analyse data and generate insights from complex multimodal data sets and different diagnostic modalities.
Acutis will develop the new genomic assay, based on its regulatory-approved lab-developed tests (LDTs) that support clinical trials, cancer research and treatment.
The company will combine SOPHiA DDM for Hereditary Cancers Solution with its laboratory analysis technologies, to create the new assay.
The new test is said to support genomic screening for patient enrolment in cancer trials and for retrospective analyses to help explain clinical outcomes and drug target discovery.
Acutis Diagnostics chief scientific officer and executive vice president Abdel Halim said: “The use of SOPHiA DDM will help us quickly launch this new assay to aid clinical researchers in speeding up the process for launching select clinical oncology trials and ensuring the most appropriate patients are enrolled.
“Additionally, the test is to provide researchers with a robust set of data and insights to support clinical decision-making and future research.”
SOPHiA GENETICS said that its NGS-based hereditary cancer solutions use artificial intelligence (AI) and machine learning (ML) technologies, with its patented technologies.
The technologies enable clinical researchers to accurately characterise the complex mutational landscape related to major hereditary cancer disorders.
Using SOPHiA GENETICS’ technology, the new assay from Acutis Diagnostics is expected to enhance clinical research and treatments for those with hereditary cancers.
SOPHiA GENETICS chief revenue officer Ken Freedman said: “Our work at SOPHiA GENETICS is focused on creating technology and solutions that make it easier for everyone to practice and benefit from data-driven medicine.
“The new assay from Acutis Diagnostics will be designed to enable clinical researchers to work faster, and with a sound set of insights around their data, ultimately benefitting their current and future patients, as well as the industry as a whole.”